phrykt

Replimune Group, Inc. (REPL): who owns it and who trades it

As of Nov 16, 2026, REPL insiders reported 19 open-market sales worth $2.5M and no purchases in the last 12 months, with 11% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sushil Patel (CEO), with $811K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Replimune Group

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns REPL

198 funds and institutions reported REPL shares worth $1.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 13.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP13.2%
BlackRock, Inc.10.7%
Rtw Investments, LP8.8%
Ridgeback Capital Investments L.P.8.7%
Goldman Sachs Group Inc5.4%
State Street Corp5.3%
Montanova Capital, LLC5.2%
Boxer Capital Management, LLC4.7%
Vanguard Capital Management LLC3.4%
Fcpm III Services B.v.3.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP11.05M13.16%$122MNo change
BlackRock, Inc.8.96M10.67%$99.2M+44%
Rtw Investments, LP7.41M8.83%$82M+1%
Ridgeback Capital Investments L.P.7.31M8.71%$80.9M–
Goldman Sachs Group Inc4.54M5.41%$50.3M+99%
State Street Corp4.44M5.29%$49.2M+17%
Montanova Capital, LLC4.39M5.23%$48.6M+4%
Boxer Capital Management, LLC3.98M4.74%$44.1M+239%
Vanguard Capital Management LLC2.90M3.45%$32.1M+5%
Fcpm III Services B.v.2.81M3.35%$31.1MNo change
AQR Capital Management LLC2.57M3.06%$28.4M+904%
Logos Global Management LP2.50M2.98%$27.7M–
Jane Street Group, LLC2.32M2.77%$25.7M+442%
Erste Asset Management GmbH2.12M2.53%$23.7MNo change
Geode Capital Management, LLC2.04M2.42%$22.5M+13%
D. E. Shaw & Co., Inc.1.79M2.13%$19.8M-23%
T. Rowe Price Associates1.62M1.93%$17.9M-80%
Opaleye Management Inc.1.38M1.65%$15.3M–
Toronto Dominion Bank1.27M1.52%$14.1M-20%
UBS Group AG1.13M1.34%$12.5M+94%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, REPL insiders reported $0 of open-market purchases and $2.5M of sales. 11% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.5M
19 trades, 8 people
Sales under a 10b5-1 plan
11%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 10, 2026

Purchases and sales by month

$1M$1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Joseph P SlatteryDirectorSale5,200$21.80$113KForm 4
Nov 2, 2026Kapil DhingraDirectorSale21,500$19.00$408KForm 4
Aug 17, 2026Emily Luisa HillCFOSale9,256$14.28$132KForm 4
Aug 10, 2026Sushil PatelCEOSale39,341$12.97$510KForm 4
Aug 10, 2026Emily Luisa HillCFOSale11,448$12.97$148KForm 4
Aug 10, 2026Konstantinos XynosChief Medical OfficerSale11,447$12.97$148KForm 4
Aug 10, 2026Andrew SchwendenmanChief Accounting OfficerSale7,632$12.97$99KForm 4
Jun 1, 2026Christopher SarchiChief Commercial OfficerSale plan12,000$9.24$111KForm 4
May 18, 2026Konstantinos XynosChief Medical OfficerSale14,023$5.08$71.2KForm 4
May 18, 2026Andrew SchwendenmanChief Accounting OfficerSale7,894$5.08$40.1KForm 4
May 18, 2026Christopher SarchiChief Commercial OfficerSale8,626$5.08$43.8KForm 4
May 18, 2026Philip Astley-SparkeDirectorSale17,657$5.08$89.7KForm 4
May 18, 2026Sushil PatelCEOSale37,324$5.08$190KForm 4
May 18, 2026Emily Luisa HillCFOSale7,812$5.08$39.7KForm 4
Apr 2, 2026Christopher SarchiChief Commercial OfficerSale plan6,500$8.01$52.1KForm 4
Dec 9, 2025Kapil DhingraDirectorSale3,169$10.40$33KForm 4
Dec 2, 2025Sushil PatelCEOSale plan10,000$11.13$111KForm 4
Nov 17, 2025Christopher SarchiChief Commercial OfficerSale5,208$9.10$47.4KForm 4
Nov 17, 2025Konstantinos XynosChief Medical OfficerSale7,248$9.10$66KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Sushil PatelChief Executive Officer, Director–$811KAug 10, 2026
Kapil DhingraDirector–$441KNov 2, 2026
Emily Luisa HillChief Financial Officer–$320KAug 17, 2026
Konstantinos XynosChief Medical Officer–$286KAug 10, 2026
Christopher SarchiChief Commercial Officer–$254KJun 1, 2026
Andrew SchwendenmanChief Accounting Officer–$139KAug 10, 2026
Joseph P SlatteryDirector–$113KNov 9, 2026
Philip Astley-SparkeDirector–$89.7KMay 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

REPL short interest

Very high short interest. 26.0% of REPL shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 24.61M REPL shares were sold short, 26.0% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.96M shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

26.0%May 15Oct 3033.8%

Days to cover

8.3May 15Oct 3014.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202624.61M25.96%+6%2.96M8.3
Oct 15, 202623.17M27.60%+0%1.82M12.7
Sep 30, 202623.13M27.55%+2%2.14M10.8
Sep 15, 202622.75M27.11%-3%2.04M11.1
Aug 31, 202623.52M28.02%-5%2.65M8.9
Aug 14, 202624.87M29.62%-10%6.28M4.0
Jul 31, 202627.54M32.81%+16%8.45M3.3
Jul 15, 202623.65M28.18%-0%2.50M9.4
Jun 30, 202623.67M28.19%+3%3.72M6.4
Jun 15, 202622.89M27.72%-12%4.73M4.8
May 29, 202625.95M31.43%+10%8.83M2.9
May 15, 202623.66M28.65%+12%8.36M2.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Replimune Group company events

Replimune Group filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 28, 2026.

  1. Oct 28, 2026ResultsReleased financial results. Filing
  2. Sep 16, 2026VoteReported shareholder vote results. Filing
  3. Aug 14, 2026ResultsReleased financial results. Filing
  4. Aug 11, 2026AnnouncementAmended an earlier report. The Company entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company’s common stock… Filing
  5. Aug 10, 2026AnnouncementReplimune Group, Inc. entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (each, an “Underwriter” and, collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 9,701,490 shares of the Company’s… Filing
  6. Aug 7, 2026AnnouncementReplimune Group, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted accelerated approval for TUDRIQEV TM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced… Filing
  7. Jul 31, 2026AnnouncementReplimune Group, Inc. issued a press release announcing that the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee met to discuss the Company’s Biologics License Application resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for… Filing
  8. Jul 30, 2026AnnouncementShared information with investors. Filing
  9. Jun 29, 2026ResultsReleased financial results. Filing
  10. Jun 26, 2026AnnouncementShared information with investors. Filing
  11. May 29, 2026AnnouncementShared information with investors. Filing
  12. Apr 13, 2026AnnouncementThe Company received a second Complete Response Letter from the FDA regarding the Company’s BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. Filing
  13. Feb 3, 2026AgreementReplimune Group, Inc. and certain subsidiaries of the Company entered into a Third Amendment to Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent, and certain other financial institutions that from time to time may become parties… Filing
  14. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Replimune Group financials

Famous investors that hold REPL

3 of the 50 well-known investors we track reported holding REPL in their latest 13F filing. The largest position is Ken Griffin's, worth $16.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.27M$16.8M0.0%+62%
Israel Englander · Millennium ManagementQ3 2026522,183$6.9M0.0%-36%
Jim Simons · Renaissance TechnologiesQ3 2026206,800$2.7M0.0%+420%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named REPL in the last 120 days.

FiledHolderFormStake
Nov 16, 2026RTW Investments, LP13G/A9.0%
Nov 16, 2026RTW Investments, LP13G/A9.0%
Nov 10, 2026STATE STREET CORPORATION13G4.4%
Nov 10, 2026STATE STREET CORPORATION13G4.4%
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G/A3.3%
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G/A3.3%

Questions about Replimune Group, Inc. (REPL) stock

Who owns the most REPL stock?

The largest reported owner of Replimune Group, Inc. (REPL) is Baker Bros. Advisors LP, with 13.2% of the company. In total, 198 funds and institutions reported holding REPL at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are REPL insiders buying or selling?

In the last 12 months, REPL insiders reported no open-market purchases and 19 sales worth $2.5M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in REPL?

As of Oct 30, 2026, 24.61M REPL shares were sold short, 26.0% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.96M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold REPL?

3 of the 50 well-known investors we track reported REPL in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $16.8M. See all holders.

Executive pay

Replimune Group's chief executive was paid a total of $5.8M for the year ended Mar 31, 2026, up 58% from $3.7M the year before. In the last 12 months, Replimune Group's executives and directors bought no stock on the open market and sold $2.5M.

Chief executive, total pay$5.8MYear ended Mar 31, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.